Prosecution Insights
Prosecution Insights
Tech Center 1600 • Art Units: 1624 1625
This examiner grants 79% of resolved cases
| App # | Title | Status | Assignee |
|---|---|---|---|
| 17601705 | ALLOPREGNANOLONE COMPOSITIONS AND USES THEREOF | Non-Final OA | The Regents of the University of California |
| 17614323 | DEUTERATED ANALOGS OF D-SERINE AND USES THEREOF | Non-Final OA | Sun Pharmaceutical Industries, Inc. |
| 18191589 | COVALENT EGFR INHIBITORS AND METHODS OF USE THEREOF | Non-Final OA | DANA-FARBER CANCER INSTITUTE, INC. |
| 18031219 | Synthesis of EGFR Modulators | Final Rejection | THE REGENTS OF THE UNIVERSITY OF MICHIGAN |
| 18437748 | SYNTHESIS AND NOVEL SALT FORMS OF (R)-5-((E)-2-(PYRROLIDIN-3-YLVINYL)PYRIMIDINE | Non-Final OA | OYSTER POINT PHARMA, INC. |
| 17435594 | Botanical Extracts and Compounds from Castanea Plants and Methods of Use | Non-Final OA | Emory University |
| 17428296 | ANTIMICROBIAL ACTIVITY OF FATTY ACID ESTERS AND COMBINATIONS THEREOF | Non-Final OA | SYMRISE AG |
| 18249421 | METHOD OF PRODUCING 3-METHYL-4-HALO-INDOLE DERIVATIVE | Non-Final OA | DAIICHI SANKYO COMPANY, LIMITED |
| 18486889 | SALT FORMS OF IRAK4 DEGRADERS | Non-Final OA | Kymera Therapeutics, Inc. |
| 18027168 | METHOD FOR MODULATING WEIGHT | Non-Final OA | Yeda Research and Development Co. Ltd. |
| 18044941 | USE OF CANNABIDIVARIN IN THE TREATMENT OF SEIZURES ASSOCIATED WITH RARE EPILEPSY SYNDROMES RELATED TO GENETIC ABNORMALITIES | Non-Final OA | Jazz Pharmaceuticals Research UK Limited |
| 17975028 | USE OF DIHYDROBERBERINE OR ITS DERIVATIVES FOR ANTI-AGING | Final Rejection | NANJING NUTRABUILDING BIO-TECH CO., LTD. |
| 17611730 | COMPOSITIONS AND METHODS FOR PREVENTING INFLAMMATORY CONDITIONS | Final Rejection | Trustees of Tufts College |
| 18007369 | USES OF GLUCOCORTICOID RECEPTOR (GR) ANTAGONIST AND ANDROGEN RECEPTOR (AR) DEGRADER COMBINATIONS | Non-Final OA | ORIC Pharmaceuticals, Inc. |
| 18259112 | SUBSTITUTED IMIDAZO[1,5-b]PYRIDAZINE COMPOUNDS AS KINASE INHIBITORS AND USE THEREOF | Non-Final OA | IMPACT THERAPEUTICS (SHANGHAI), INC |
| 17913118 | NOVEL COMPOSITIONS FOR TREATMENT OF CORONAVIRUS DISEASE | Non-Final OA | Laurent Pharmaceuticals Inc. |
| 17790961 | COLLAGEN 1 TRANSLATION INHIBITORS AND METHODS OF USE THEREOF | Non-Final OA | Anima Biotech Inc. |
| 17822399 | STABLE PHARMACEUTICAL COMPOSITIONS OF SUCCINYLCHOLINE CHLORIDE | Non-Final OA | Slayback Pharma LLC |
| 17636476 | APPLICATION OF FLUORO-SUBSTITUTED 2-AMINOTHIAZOLE-5-AROMATIC CARBOXAMIDE | Non-Final OA | HUNAN WARRANT PHARMACEUTICAL TECHNOLOGY DEVELOPMENT CO., LTD |
| 17635459 | PIMAVANSERIN FOR TREATING NEURODEGENERATIVE DISEASES | Non-Final OA | ACADIA Pharmaceuticals Inc. |
| 17629464 | METHOD OF REDUCING BIOFILM FORMATION AND TREATING FUNGAL INFECTION BY FUNGAL CELLS | Non-Final OA | Karl-Franzens-Universität Graz |
| 17432839 | mTOR Inhibitor | Non-Final OA | Kazumoto Murata |
| 17607352 | Bio-Based Medicines and Methods of Increasing Patient Compliance | Final Rejection | RDE PHARMA |
IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.
Build Your Strategy